Quote:

---

I did want to ask you your thoughts on how the mTNBC tumors essentially vanished, thereby leading to the OS of 36 going on 48 months and the claim of no evidence of disease.

---

Carboplatin or other compounds being used are going to be killing off tumor cells usually by brute attack or damaging DNA, but very rarely does a complete job. Why? Standard treatments can cause tumor cells to break free from the main tumor and can escape attack by chemotherapy and radiation and reestablish tumors. Metastatic tumor cells are particularly tenacious because they can go dormant for longer periods of time and start multiplying again.

Leronlimab stops the damaged cells from repairing DNA resulting in cell death. Strips away the levels of tumor defense leaving them vulnerable to the killer T-cells that leronlimab increases. It halts the growth factors that tumor cells need for multiplication. It also stops the movement of metastatic tumor cells. That explains the initial eradication of the cancer.

Cancer often comes back even after all signs of it are gone. Genetics can play a role by predisposing regular cells to mutate into cancerous cells, sometimes by increasing inflammatory factors. Insult driven inflammation can also force genetic mutation turning cells cancerous. With genetic mutations I think only maintenance doses of leronlimab could keep cancer at bay. Spontaneous mutations also occur often which can cause inflammation and the concurrent anti-inflammatory factors which the tumor hi-jacks to protect itself. With insult driven inflammation or spontaneous mutations leronlimab may eliminate that inflammation and accompanying anti-inflammatory factors reducing the chance for new mutations to occur.

Guesswork on my part since very extensive testing of patients was assuredly not done under Amarex. Until that is done either in a follow up study of the current mTNBC patients or in a phase 3 we won't have the proof.